B
BOYDSense
BOYDSense - Health monitoring made simple powered by breath
About BOYDSense
BOYDSense, an award-winning startup with R&D in France and the U.S., is a pioneer in the development of non-invasive breath analysis solutions for the risk stratification, screening, monitoring and detection of different biomarkers. BOYDSense is currently developing its first product, a miniaturized breath analyzer for monitoring glucose concentration in pre-diabetics and type 2 diabetics. The device detects the type and concentration of volatile organic compounds in breath. The solution is pain-free, affordable, and produces significantly less waste compared to existing fingerstick blood glucose or continuous glucose monitors.
Source: Dealroom company dataAt a glance
- Founded
- 2020
- Headquarters
- Toulouse, France
- Sector
- Health Tech & Medtech
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
European Innovation Council
Series A6 investors entered at this stage
Alpha Mos
EIC Fund
Jolt Capital
Swiss Diabetes Venture Fund
BioSerenity
Industrial Organic
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BOYDSense on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BOYDSense on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.